AAV-mediated Siglecf elimination on TAMs reverses TMZ therapy-induced T cell dysfunction in glioblastoma.
Glioblastoma (GBM) is the most aggressive primary tumor of the brain, characterized by extensive intratumor heterogeneity, and exhibits inevitable recurrence despite conventional therapy. This study investigates the immunosuppressive mechanisms underlying GBM recurrence following temozolomide (TMZ) therapy, with a spec...